Observational studyEuropean heart journal. Cardiovascular Imaging2025
CarDiac magnEtic Resonance for prophylactic Implantable cardioVerter defibrillAtor ThErapy in Non-Dilated Left Ventricular Cardiomyopathy: a sub-study from the DERIVATE registry.
Observational study in European heart journal. Cardiovascular Imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07351838 (Prognosis and Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognosis and Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy : Cardiac MRI Insights for Better Outcomes
Who cites it
12 citing papers in PubMed.
- Cardiovascular magnetic resonance for therapy monitoring in cardiomyopathies.European heart journal. Imaging methods and practice · 2026Review
- Cardiac MRI Across ESC Guidance in the Last Decade.Clinical cardiology · 2026Review
- Non-Dilated Left Ventricular Cardiomyopathy (NDLVC): A Name, Multiple Souls.Current cardiology reports · 2026Review
- Evaluation of non-dilated left ventricular cardiomyopathy patients with reduced and preserved left ventricular ejection fraction using cardiac magnetic resonance feature tracking technology.BMC cardiovascular disorders · 2026Article
- Unmasking the Apex: Multimodality Imaging for the Evaluation of Left Ventricular Apical Obliteration.Diagnostics (Basel, Switzerland) · 2026Review
- Multimodal Imaging Evaluation of Non-Dilated Left Ventricular Cardiomyopathy: The Importance of Cardiac Magnetic Resonance Imaging.International medical case reports journal · 2026Article
- A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy.The international journal of cardiovascular imaging · 2025Article
- The Evolving Role of Cardiac Imaging in Hypertrophic Cardiomyopathy: Diagnosis, Prognosis, and Clinical Practice.Biomedicines · 2025Review
- Left Ventricular Ring-like Pattern: The Arrhythmic Tale of a Scarred Heart.Journal of cardiovascular development and disease · 2025Review
- Cardiac Magnetic Resonance Guidance for the Pathogenetic Definition of Cardiomyopathies.Current cardiology reports · 2025Review
- Acute Heart Failure and Non-Ischemic Cardiomyopathies: A Comprehensive Review and Critical Appraisal.Diagnostics (Basel, Switzerland) · 2025Review
- Feasibility and Role of Cardiac Magnetic Resonance in Intensive and Acute Cardiovascular Care.Journal of clinical medicine · 2025Review
Corrections and comments
- Commented on by
Authors and funding
62 authors.
Funding
Abstract
aimsAccurate risk stratification for patients with non-dilated left ventricular cardiomyopathy (NDLVC) remains challenging due to lack of dedicated clinical trials. This post hoc analysis aims to delineate the arrhythmic risk and assess the incremental value of cardiac magnetic resonance (CMR) imaging in the CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy (DERIVATE) study cohort meeting the NDLVC diagnostic criteria. METHODS AND
resultsPatients with NDLVC from the DERIVATE registry were identified in the absence of left ventricular (LV) dilatation and in the presence of non-ischaemic LV scarring ('fibrotic NDLVC') or isolated LV systolic dysfunction (LV ejection fraction < 50%) without fibrosis ('hypokinetic NDLVC'). The primary endpoint was all-cause mortality. Major adverse arrhythmic cardiac events (MAACE) were the secondary endpoint and included sudden cardiac death (SCD) and aborted SCD. One hundred and ninety-seven NDLVC patients were identified from the cohort of the DERIVATE study (mean age: 59 ± 14 years; male: 135). Over a median follow-up of 2.7 years, 15 (8%) patients died and 8 (4%) experienced MAACE. Patients with 'hypokinetic' NDLVC had significantly lower rates of MAACE than non-ischaemic dilated cardiomyopathy (NIDCM) (P = 0.001), while patients with 'fibrotic' NDLVC had same rate of both primary (P = 0.48) and secondary endpoints (P = 0.616) compared with NIDCM patients. Multivariable analysis identified late gadolinium enhancement (LGE) with midwall distribution as an independent predictor of MAACE in NDLVC patients (hazard ratio 6.7, 95% confidence interval: 1.33-33.67; P = 0.021).
conclusionNDLVC patients exhibit a heterogeneous risk profile for arrhythmic events. The presence of midwall LGE, similarly to NIDCM, is a significant predictor of MAACE, highlighting the importance of CMR imaging for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.